Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC)
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.115938 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Xiang Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry & Chemical Engineering, Inner Mongolia University, Hohhot, Inner Mongolia 010020, PR China; Biosion Inc., Nanjing, Jiangsu, PR Ch…. Hauptthemen laut MEDLINE: RNA, Small Interfering, Immunoconjugates, Camptothecin, Neoplasms. Die Arbeit nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Antibody-siRNA conjugate (ARC) is a novel therapeutic strategy developed based on the concept of antibody-drug conjugate (ADC). It combines the targeting specificity of antibodies with the gene silencing ability of small interfering RNA (siRNA) and shows broad application prospects. However, the development of traditional ARC in the field of tumor treatment faces many challenges, and the DNA Topoisomerase I Inhibitor-Exatecan is limited in its clinical application due to its strong hydrophobicity and significant toxicity. In this study, we developed a novel antibody-siRNA-Exatecan conjugate (AREC). By introducing siRNA, we plan to increase the hydrophilicity of small molecule drugs and optimize the drug to antibody ratio (DAR) to 1 and 2. This modification not only significantly reduced the toxic side effects associated with high DAR values, but also provided a basis for evaluating the synergistic anti-tumor effect between STAT3 gene silencing and Exatecan. In vitro experimental results showed that AREC can efficiently kill tumor cells, fully demonstrating its great potential as a multifunctional platform for tumor targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry & Chemical Engineering, Inner Mongolia University, Hohhot, Inner Mongolia 010020, PR China; Biosion Inc., Nanjing, Jiangsu, PR China.
- Biosion Inc., Nanjing, Jiangsu, PR China.
- Center of Clinical Laboratory Medicine, Jiangbei Campus, Zhongda Hospital, Southeast University, Nanjing 210048, PR China.
- Biosion Inc., Nanjing, Jiangsu, PR China. Electronic address: mingjiu.chen@biosion.com.
- School of Chemistry & Chemical Engineering, Inner Mongolia University, Hohhot, Inner Mongolia 010020, PR China. Electronic address: hbaigude@imu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yu, X., Ma, Z. M., Ji, F., Chen, M., & Baigude, H. (2026). Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC). International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115938
Vancouver
Yu X, Ma ZM, Ji F, Chen M, Baigude H. Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC). International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.115938
BibTeX
@article{Yu2026,
author = {Yu, Xiang and Ma, Ze Meng and Ji, Feng and Chen, Mingjiu and Baigude, Huricha},
title = {Preparation and in vitro functional validation of a novel antibody-siRNA-Exatecan conjugate (AREC)},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.115938}
}
EUVIMED